FDA Seeks Industry Collaboration on Medical Device Active Surveillance System
The FDA is seeking input from organizations interested in collaborating with the agency on the development and execution of the medical device active surveillance system. “Once realized, such a system will optimize data collection, quality, completeness, and analysis within a comprehensive framework to assess potential and ongoing safety signals in a timely manner,” said the FDA in its call for sources.
Businesses of all sizes on GSA MAS Schedule 54151HEAL Health Information Technology Services with the capabilities to provide the services stated may submit a response. Businesses that do not have a contract on this schedule or any GSA schedule may submit a response as well, and small businesses are encouraged to submit a response. Interested parties must respond by March 20, 2023, at 10:00am EST.
The FDA notes that it is issuing this “source sought” notice as a means of conducting market research, pursuant to FAR Part 10 Market Research, to identify potential parties from the marketplace capable of providing professional services for the Center for Devices and Radiological Health’s (CDRH) requirement for Medical Device Active Surveillance System. The information being sought is purely voluntary and for planning purposes only.
Those interested in joining the collaboration can find more information here.
Related Articles
-
The purpose of the Best Practices in Supply Chain Resiliency and Quality Working Group is to improve medical device quality and supply chain resiliency by expanding MedAccred adoption through the tiers in the supply chain, identifying best practices to supplement…
-
Steps to ensure your medical device labels are in compliance with global regulations and have the longevity to withstand your device’s intended use.
-
The UK MHRA has published “Software and Artificial Intelligence as a Medical Device.” The guidance document assembles previous guidances and regulatory requirements for SaMD and AIaMD devices seeking commercialization in the UK market.
-
Jordi labs and its team of Ph.D. analytical chemists developed a proprietary, multi-detector approach to ensure that all extractables are accurately characterized to comply with global materials testing regulatory requirements.
